Results 1 to 10 of about 9,393 (236)
Oxidation of Mesalamine under Phenoloxidase- or Peroxidase-like Enzyme Catalysis
Molecules, 2023 Mesalamine, also called 5-ASA (5-aminosalicylic acid), is a largely used anti-inflammatory agent and is a main choice to treat Ulcerative Colitis. This report is aimed to investigate enzymatic processes involved in the oxidation of mesalamine to better ...
Rimaz El Zein +4 more
doaj +2 more sources
Mesalamine-Induced Myocarditis [PDF]
Cardiology Research and Practice, 2010 Nowadays mesalamine is a common treatment for Crohn's disease and hypersensitive reactions to this product have been reported. Yet there is limited information concerning mesalamine-induced myocarditis and its mechanism is not known.
Olivier Merceron +6 more
doaj +3 more sources
Gels, 2023 This research aims to develop a drug delivery system that effectively treats colitis while administering curcumin/mesalamine by coating alginate/chitosan beads with Eudragit® S-100 to target the colon. Beads were tested to determine their physicochemical
Eman J. Heikal +8 more
doaj +2 more sources
Frontiers in Pharmacology, 2021 Mesalamine has been well used in the improvement of ulcerative colitis (UC) in clinics, however, the underlying mechanisms were not well illustrated. To explore its efficacy from the perspective of gut microbiota and related metabolites, we employed 16S ...
Liang Dai +8 more
doaj +2 more sources
Exacerbation of Bloody Diarrhea as a Side Effect of Mesalamine Treatment of Active Ulcerative Colitis [PDF]
Case Reports in Gastroenterology, 2011 Mesalamine has been used as the first-line therapy for the treatment of ulcerative colitis (UC) because of its efficacy and fewer side effects. However, earlier study showed that mesalamine occasionally causes diarrhea.
Yuichi Shimodate +5 more
doaj +2 more sources
Journal of Investigative Surgery, 2023 Objective: This study is aimed at investigating the impact of mesalamine combined with Live combined Bifidobacterium, Lactobacillus and Enterococcus capsules on intestinal mucosa barrier function and intestinal microbiota in mildly active Crohn’s disease
Meiqin Shen +3 more
doaj +2 more sources
Recent advances in mesalamine colonic delivery systems
Future Journal of Pharmaceutical Sciences, 2020 Background Increased attention has been focused on the continuous development and improvement of mesalamine colonic specific delivery systems, for the effective treatment of inflammatory bowel diseases; thus enhancing therapeutic efficacy and reducing ...
Mohammad F. Bayan, Rana F. Bayan
doaj +2 more sources
Mesalamine induced eosinophilic pneumonia
Respiratory Medicine Case Reports, 2017 We present the case of a twenty two year old Caucasian male with ulcerative colitis on mesalamine who presented with dry cough, fever, malaise and dyspnea on exertion.
Ankit Gupta, MD, MS +1 more
doaj +3 more sources
A Comparison of Budesonide and Mesalamine for Active Crohn's Disease [PDF]
New England Journal of Medicine, 1998 Crohn's disease is often treated with glucocorticoids or mesalamine. We compared the efficacy and safety of controlled-ileal-release budesonide capsules and slow-release mesalamine tablets in patients with active Crohn's disease affecting the ileum, the ascending colon, or both.In a double-blind, multicenter trial, we enrolled 182 patients with scores ...
Antoine Cortot +8 more
openaire +4 more sources
Clinical and Experimental Gastroenterology, 2009 Glen A Doherty, Mark A PeppercornCenter for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston MA, USAAbstract: 5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative ...
Glen A Doherty, Mark A Peppercorn
doaj +3 more sources